SCHEMBL1797472

SCHEMBL1797472

Cc1nc(-c2cn(S(=O)(=O)c3ccccc3)c3ncc(C4CCC(N5CCN(C)CC5)CC4)cc23)cs1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.39
HTR6 P50406 1/20 0.38
ACVR1 Q04771 9/20 0.38
BMPR1B O00238 1/20 0.38
BMPR1A P36894 1/20 0.38
ACVR1B P36896 1/20 0.38
TGFBR1 P36897 1/20 0.38
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
GAA P10253 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
IRS1 P35568 1/20 0.34
GAB1 Q13480 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8176886 1.00 BRD4 (0.43) BRD4SMN1; SMN2HTR6ACVR1BMPR1B
SCHEMBL1797475 1.00 BRD4 (0.43) BRD4SMN1; SMN2HTR6ACVR1BMPR1B
SCHEMBL1799104 0.94 BRD4 (0.45) BRD4SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL1799102 0.94 BRD4 (0.45) BRD4SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL1799812 0.92 BRD4 (0.45) BRD4SMN1; SMN2ACVR1BMPR1BBMPR1A
SCHEMBL8167338 0.92 BRD4 (0.45) BRD4SMN1; SMN2ACVR1BMPR1BBMPR1A
SCHEMBL1799810 0.92 BRD4 (0.45) BRD4SMN1; SMN2ACVR1BMPR1BBMPR1A
SCHEMBL8176428 0.91 ACVR1 (0.37) BRD4SMN1; SMN2HTR6ACVR1BMPR1B
SCHEMBL1798577 0.91 ACVR1 (0.37) BRD4SMN1; SMN2HTR6ACVR1BMPR1B
SCHEMBL1798579 0.91 ACVR1 (0.37) BRD4SMN1; SMN2HTR6ACVR1BMPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE MAPK7, MAPKAPK5, MAPK13 BRD4 728/4885SMN1; SMN2 1124/4885HTR6 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.